6 Journal of International Economic Law 733-37 (2003)
Download below
Out of the expanse of Bob Hudec’s many contributions, there is perhaps none that has been (or will be) more widely read and commented on than the report of the WTO dispute settlement panel in Canada-Patent Protection of Pharmaceutical Products (“Canada-Generic Pharmaceuticals”), for which Bob served as Chair. The decision rendered by the panel in Canada-Generic Pharmaceuticals, which was not appealed, is certainly the most important analysis of the TRIPS Agreement to date.
